Log in

Relevant bibliographies by topics / Blueprint A 3.0 / Journal articles

To see the other types of publications on this topic, follow the link: Blueprint A 3.0.

Journal articles on the topic 'Blueprint A 3.0'

Author: Grafiati

Published: 24 June 2021

Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Blueprint A 3.0.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bocchi, V., M. G. Strillacci, A. Zecconi, et al. "191 SEARCHING FOR THE IN VIVO TRANSCRIPTOME BLUEPRINT OF COMPETENT BOVINE OOCYTES." Reproduction, Fertility and Development 28, no. 2 (2016): 226. http://dx.doi.org/10.1071/rdv28n2ab191.

Full text

Abstract:

Gene expression in early stage embryos relies mostly on post-transcriptional control of maternal transcripts accumulated during oocyte maturation. However, while the building process to obtain a competent oocyte is now better understood, it is still not clear what transcriptome blueprint composes a competent oocyte. The aim of the study was to compare the mRNA expression pattern between oocytes collected from fertile heifers and repeat breeders by using RNAseq. Oocytes were collected by ovum pickup from 3 heifers that were 11–15 months of age and became pregnant at the following oestrus and fr

APA, Harvard, Vancouver, ISO, and other styles

2

Pinato, David James, Francesco A. Mauri, Paolo Spina, et al. "Quantitative comparison of PD-L1 immuno-histochemical assays in hepatocellular carcinoma: The Blueprint-HCC study." Journal of Clinical Oncology 36, no. 5_suppl (2018): 91. http://dx.doi.org/10.1200/jco.2018.36.5_suppl.91.

Full text

Abstract:

91 Background: Programmed cell death ligand 1 (PD-L1) expression by immunohistochemistry (IHC) enriches for responses to PD-1/PD-L1 inhibitors, however its role as a predictive biomarker in hepatocellular carcinoma (HCC) is inconclusive, with no consensus on any particular assay. We evaluated the performance of 4 different PD-L1 detection assays previously published in landmark clinical studies. Methods: PD-L1 IHC was performed on 4 serial sections from tissue microarray (TMA) blocks containing 100 archival cases of HCC that included tumour and surrounding non-tumorous tissue. Antibody clones

APA, Harvard, Vancouver, ISO, and other styles

3

Roper, Michael. "Effective Knowledge Management: A Best Practice Blueprint20036Sultan Kermally. Effective Knowledge Management: A Best Practice Blueprint. Chichester: John Wiley & Sons 2002. 194 pp., ISBN: ISBN 0 470 844493 3 £24.95." Journal of Documentation 59, no. 1 (2003): 118–19. http://dx.doi.org/10.1108/00220410310458082.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Othman, Zarith Sofiah, Nurhuda Ismail, Ahmad Khudzairi Khalid, and Norbaiti Tukiman. "Module Development for STEM Education Achievement: A Case Study at the Secondary School Level." Journal of Computational and Theoretical Nanoscience 17, no. 2 (2020): 1085–89. http://dx.doi.org/10.1166/jctn.2020.8771.

Full text

Abstract:

STEM Education through the Malaysia Education Blueprint 2013–2025 (PPPM 2013–2025) is an important agenda in the transformation of education to prepare the younger generation for the challenges of the 21st century. Over the years, STEM was carried out, but there are still some issues which contribute towards the failure in achieving a policy percentage set of 60% science and 40% literary studies in secondary schools. The target to increase the number of Science students was not achieved. Therefore, this study was conducted to produce a STEM@IDEAS module as an alternative to increase students’

APA, Harvard, Vancouver, ISO, and other styles

5

Maggio, Meg. "The Hong Kong Basic Law: Blueprint for “Stability and Prosperity” under Chinese Sovereignty? Edited by Ming K. Chan and David J. Clark. [New York: M. E. Sharpe, 1991. 310 pp. ISBN 0-87332-835-3.]." China Quarterly 153 (March 1998): 169–71. http://dx.doi.org/10.1017/s030574100000312x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Robinson, JoAnn L. "A Blueprint for the Promotion of Prosocial Behavior in Early Childhood. E. Chesebrough, P. King, T. P. Gullotta, & M. Bloom (Eds.). New York: Springer, 2004, $65.00 (Hardcover), 320 pp., ISBN 0-30648-186-3." Journal of Primary Prevention 27, no. 4 (2006): 445–46. http://dx.doi.org/10.1007/s10935-006-0044-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gotlib, Jason, Deepti H. Radia, Tracy I. George, et al. "Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study." Blood 136, Supplement 1 (2020): 37–38. http://dx.doi.org/10.1182/blood-2020-137413.

Full text

Abstract:

Introduction: Advanced systemic mastocytosis (AdvSM) comprises a heterogeneous group of clonal mast cell neoplasms, primarily driven by KIT D816V. Measures of AdvSM response, including the International Working-Group for Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (IWG-MRT-ECNM) criteria, are based on improvements in mast cell-related organ damage (C-findings), and further sub-classified by the extent of reduction in measures of mast cell disease (e.g. serum tryptase level, bone marrow mast cell burden). However, assessment of some C-find

APA, Harvard, Vancouver, ISO, and other styles

8

Maltin, C. A., G. E. Lobley, C. M. Grant, et al. "Factors influencing beef eating quality 2. Effects of nutritional regimen and genotype on muscle fibre characteristics." Animal Science 72, no. 2 (2001): 279–87. http://dx.doi.org/10.1017/s1357729800055776.

Full text

Abstract:

AbstractEighteen purebred steers of three genotypes, Aberdeen Angus (AA), Charolais (CH) and Holstein (HO), were divided within genotype into three groups of six animals and offered one of three different levels of feeding either moderate (M/M) or high (H/H) both for 20 weeks or moderate for the first 10 weeks followed by high for the remaining 10 weeks (M/H). Growth rates during the final 10 weeks of the experimental period differed between dietary regimen (M/M = 0·87; M/H = 1·25; and H/H = 1·02 kg/day; s.e.d. = 0·08;P< 0·001). Over the entire 20 week experimental period animals offered th

APA, Harvard, Vancouver, ISO, and other styles

9

Gotlib, Jason R., Deepti Radia, Daniel J. DeAngelo, et al. "Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM)." Blood 132, Supplement 1 (2018): 351. http://dx.doi.org/10.1182/blood-2018-99-112017.

Full text

Abstract:

Abstract Introduction: The KIT D816V oncogene is a key driver in 90-95% of patients with systemic mastocytosis (SM), a group of mast cell (MC) neoplasms including indolent SM (ISM), smoldering SM (SSM) and AdvSM. Debilitating symptoms related to MC proliferation and degranulation characterize ISM and SSM and are also prominent in AdvSM, which is further complicated by SM-related organ damage and decreased survival. Currently, there are no approved agents that selectively target KIT D816V, and there are limited tools to assess symptom improvement in SM. Avapritinib, a highly potent and selectiv

APA, Harvard, Vancouver, ISO, and other styles

10

Goodhart, William. "The Hong Kong Basic Law—Blueprint for “Stability and Prosperity” under Chinese Sovereignty?. Edited by Ming K. Chan and David J. Clark. [New York: M. E.Sharpe East Gate Books. 1991. xv + 310 pp. ISBN 0-87332-835-3. $45]." International and Comparative Law Quarterly 41, no. 4 (1992): 963–64. http://dx.doi.org/10.1093/iclqaj/41.4.963.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Bowyer-Bower, T. A. S., and David Pearce. "Blueprint 3: Measuring Sustainable Development." Geographical Journal 162, no. 1 (1996): 114. http://dx.doi.org/10.2307/3060278.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Beckerman, Wilfred. "Blueprint 3: measuring sustainable development." International Affairs 70, no. 3 (1994): 560. http://dx.doi.org/10.2307/2623760.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Walsingham, Jean. "Blueprint 3 — Measuring sustainable development." Agricultural Systems 52, no. 4 (1996): 525–26. http://dx.doi.org/10.1016/s0308-521x(96)80457-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Owens, Peter L. "Blueprint 3: measuring sustainable development." Applied Geography 14, no. 3 (1994): 282. http://dx.doi.org/10.1016/0143-6228(94)90043-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Owens, Susan. "Blueprint 3: Measuring sustainable development." Global Environmental Change 5, no. 1 (1995): 78–79. http://dx.doi.org/10.1016/0959-3780(95)90015-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Oetjen, Karolyn, Cai Chen, Christian Bradley, et al. "Neoantigen Landscape of Relapsed Acute Leukemia Following Allogeneic Stem Cell Transplantation." Blood 132, Supplement 1 (2018): 4595. http://dx.doi.org/10.1182/blood-2018-99-115501.

Full text

Abstract:

Abstract INTRODUCTION: The potent graft versus leukemia (GVL) effect of allogeneic stem cell transplantation (allo-SCT) is considered as a blueprint for cellular immunotherapy. However, failure of GVL leads to relapse of underlying leukemia, the major cause of death after allo-SCT. In solid tumors, higher tumor mutation burdens are associated with better response to check point inhibitors which implies the importance of neoantigen specific T-cell functions in cancer immunity. In contrast, the frequencies of somatic mutations in acute leukemia are generally low, therefore the role of neoantigen

APA, Harvard, Vancouver, ISO, and other styles

17

Stirrups, Robert. "A blueprint for hope." Lancet Respiratory Medicine 7, no. 7 (2019): 565. http://dx.doi.org/10.1016/s2213-2600(19)30135-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Kosarewicz, Agata, Lisa Königsmaier, and Thomas C. Marlovits. "The blueprint of the type-3 injectisome." Philosophical Transactions of the Royal Society B: Biological Sciences 367, no. 1592 (2012): 1140–54. http://dx.doi.org/10.1098/rstb.2011.0205.

Full text

Abstract:

Type-3 secretion systems are sophisticated syringe-like nanomachines present in many animal and plant Gram-negative pathogens. They are capable of translocating an arsenal of specific bacterial toxins (effector proteins) from the prokaryotic cytoplasm across the three biological membranes directly into the eukaryotic cytosol, some of which modulate host cell mechanisms for the benefit of the pathogen. They populate a particular biological niche, which is maintained by specific, pathogen-dependent effectors. In contrast, the needle complex, which is the central component of this specialized pro

APA, Harvard, Vancouver, ISO, and other styles

19

Jawhar, Mohamad, Nicole Naumann, Sebastian Kluger, et al. "Inhibitory Effects of Midostaurin and Blu-285 on Myeloid Progenitor Cells Derived from Patients with Multi-Mutated KIT D816V+ Advanced Systemic Mastocytosis." Blood 128, no. 22 (2016): 1964. http://dx.doi.org/10.1182/blood.v128.22.1964.1964.

Full text

Abstract:

Abstract Recent data have highlighted that the molecular pathogenesis of advanced systemic mastocytosis (advSM) is complex. In addition to the phenotypically most important mutations in KIT, e.g. KIT D816V in 80-90% of patients, one or more additional mutations, e.g. in SRSF2, ASXL1, RUNX1, CBL, JAK2 and others, are present in 60-70% of patients (Jawhar et al., Leukemia 30, 2016). In individual patients, a complex mutational profile is detected not only in mature mast cells (MCs) but also in myeloid progenitors derived from granulocyte-macrophage colony-forming progenitor cells (CFU-GM), indic

APA, Harvard, Vancouver, ISO, and other styles

20

Laug, Dylan, Stacey M. Glasgow, and Benjamin Deneen. "A glial blueprint for gliomagenesis." Nature Reviews Neuroscience 19, no. 7 (2018): 393–403. http://dx.doi.org/10.1038/s41583-018-0014-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Ravella, Revathi, Elizabeth Ren Zhang-Velten, Farrukh T. Awan, et al. "CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A 'Real-World' Analysis of Patterns of Failure and Role of Bridging Therapy." Blood 136, Supplement 1 (2020): 22–23. http://dx.doi.org/10.1182/blood-2020-141445.

Full text

Abstract:

Introduction:In R/R DLBCL patients receiving CAR T-cell therapy (CAR-T), bridging therapy (BT) with chemotherapy, targeted therapy, and/or radiation therapy (RT) is often administered during the manufacturing window after collection and prior to CAR-T infusion to aid in tumor debulking and/or control symptomatic disease. However, little is known about the optimal type of BT and specifically, the impact BT may have on patterns of failure. Thus, we sought to compare the patterns of failure in patients who received CAR-T for R/R NHL at a single-institution based on the type of BT received. We hyp

APA, Harvard, Vancouver, ISO, and other styles

22

Bigler, Bill. "A blueprint for regenerating firms." Long Range Planning 29, no. 5 (1996): 652–62. http://dx.doi.org/10.1016/0024-6301(96)00059-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

DeAngelo, Daniel J., Brian A. Jonas, Jane L. Liesveld, et al. "Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses." Blood 132, Supplement 1 (2018): 331. http://dx.doi.org/10.1182/blood-2018-99-114286.

Full text

Abstract:

Abstract Background Binding of E-selectin (E-sel) to sialyl Lex on the leukemic cell surface activates cell survival pathways and promotes chemotherapy resistance in AML. Expression of the E-sel ligand (E-sel-L) is associated with increased relapse and poor survival. Uproleselan (GMI-1271), a novel E-sel antagonist, disrupts cell survival pathway activation, enhances chemotherapy response and protects from toxicity with improved survival in vivo. We added uproleselan to mitoxantrone, etoposide, cytarabine (MEC) chemotherapy for R/R AML patients (pts) and to cytarabine and idarubicin (7+3) indu

APA, Harvard, Vancouver, ISO, and other styles

24

Richardson, Sarah J., James Michael Fisher, and Andrew Teodorczuk. "The Future Hospital: a blueprint for effective delirium care." Future Hospital Journal 3, no. 3 (2016): 178–81. http://dx.doi.org/10.7861/futurehosp.3-3-178.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Siddiqui, Maria Tariq, Rashmi Kanagal-Shamanna, Kiran Naqvi, et al. "Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series." Blood 136, Supplement 1 (2020): 18–19. http://dx.doi.org/10.1182/blood-2020-142084.

Full text

Abstract:

INTRODUCTION: Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN RS-T), formerly called refractory anemia with ring sideroblasts and thrombocytosis (RARS-T), is a disease entity characterized by the presence of anemia, thrombocytosis, bone marrow dysplasia with ring sideroblasts and large atypical megakaryocytes. Given the rarity of MDS/MPN-RS-T, there is little data on the efficacy and clinical outcomes of different therapies in this patient population. Prior case reports and series suggest treatment with erythropoietin-stimulating agents (

APA, Harvard, Vancouver, ISO, and other styles

26

Facchini, Peter J., Jillian M. Hagel, David K. Liscombe, et al. "Opium poppy: blueprint for an alkaloid factory." Phytochemistry Reviews 6, no. 1 (2007): 97–124. http://dx.doi.org/10.1007/s11101-006-9042-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Ananthaswamy, Anil. "Quantum entanglement holds together life's blueprint." New Scientist 207, no. 2769 (2010): 9. http://dx.doi.org/10.1016/s0262-4079(10)61708-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Garcia, Jacqueline S., Helen I. Gandler, Geoffrey Fell, et al. "Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies." Blood 134, Supplement_1 (2019): 2549. http://dx.doi.org/10.1182/blood-2019-126224.

Full text

Abstract:

Background: Increased expression of hepatocyte growth factor (HGF), causing activation of its receptor MET, is found in a subset of patients with acute myeloid leukemia (AML). Inhibition of HGF-MET signaling with the specific MET kinase inhibitor crizotinib led to a transient therapeutic effect in AML cells; however, resistance rapidly emerged via increased HGF expression due to activation of alternative kinase pathways such as FGFR1 (Kentsis et al., Nat Medicine, 2012). Thus, simultaneous inhibition of activated MET and FGFR represents a potential therapeutic opportunity to forestall resistan

APA, Harvard, Vancouver, ISO, and other styles

29

Garcia-Manero, Guillermo, Koji Sasaki, Guillermo Montalban-Bravo, et al. "Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)." Blood 132, Supplement 1 (2018): 232. http://dx.doi.org/10.1182/blood-2018-99-116838.

Full text

Abstract:

Abstract Introduction: The hypomethylating agents (HMA) are the standard of care for a majority of patients with higher-risk MDS. SGI-110 is a second generation HMA that molecularly is a dinucleotide derivative of decitabine and therefore a more potent inhibitor of DNA methyltransferase activity. SGI-110 is currently being studied in front-line AML and second-line MDS multicenter studies. Here we present results of a single arm phase II trial of SGI-110 for patients with previously untreated MDS. Methods: Patients, age 18 or older, with adequate renal and hepatic functions, with int-2 or high

APA, Harvard, Vancouver, ISO, and other styles

30

Brown, Patrick A., Lingyun Ji, Xinxin Xu, et al. "A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331." Blood 134, Supplement_2 (2019): LBA—1—LBA—1. http://dx.doi.org/10.1182/blood-2019-132435.

Full text

Abstract:

First relapse of B-ALL in children and AYAs is a vexing clinical problem with high rates of subsequent relapse and death using conventional treatment approaches. This is especially true in patients with early relapse [high risk (HR), defined as marrow relapse <36 months from diagnosis or isolated extramedullary relapse <18 months from diagnosis] and those with late relapse and minimal residual disease (MRD) of ≥0.1% at the end of re-induction chemotherapy [intermediate risk (IR)]. Allogeneic hematopoietic stem cell transplant (HSCT) is considered the treatment of choice for this populati

APA, Harvard, Vancouver, ISO, and other styles

31

Guru Murthy, Guru Subramanian Guru, Scott H. Kaufmann, Aniko Szabo, et al. "A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)." Blood 134, Supplement_1 (2019): 3837. http://dx.doi.org/10.1182/blood-2019-131728.

Full text

Abstract:

Background: Outcomes of patients with AML have remained poor despite the availability of cytotoxic chemotherapy, hypomethylating agents (HMAs) and targeted therapies. HMAs, such as azacitidine, in combination with Bcl-2 inhibitors like venetoclax have demonstrated response rates of 67% in newly diagnosed AML and 21% in relapsed/refractory (RR) AML (DiNardo et al. Blood 2019 and Am J Hematol 2018). While the combination of azacitidine and venetoclax is efficacious in AML, preclinical studies indicate potential mechanisms of drug resistance including overexpression of MCL-1, an anti-apoptotic pr

APA, Harvard, Vancouver, ISO, and other styles

32

Amrein, Philip C., Karen K. Ballen, Kristen E. Stevenson, et al. "Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults." Blood 136, Supplement 1 (2020): 41–42. http://dx.doi.org/10.1182/blood-2020-139661.

Full text

Abstract:

Introduction: While progress has been made in the treatment of childhood leukemia, the outlook for patients &gt;60 years of age with acute lymphoblastic leukemia (ALL) is poor with complete remission rates (CR) of approximately 60% and 3-year survivals (OS) of less than 15%. Intensified treatment in a later CALGB trial showed little improvement with a CR=61% and 5-year OS=6% (Stock, Cancer 2013). Ixazomib is an oral proteasome inhibitor, which has shown single agent activity and promising combination activity in pediatric ALL patients (Messinger, Blood 2012). We sought to assess the safety

APA, Harvard, Vancouver, ISO, and other styles

33

Cattaneo, Adriano. "Breastfeeding in Europe: a blueprint for action." Journal of Public Health 13, no. 2 (2005): 89–96. http://dx.doi.org/10.1007/s10389-004-0089-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kvasnicka, Hans Michael, Juergen Thiele, Carlos E. Bueso-Ramos, Philomena Colucci, Dilan Paranagama, and Srdan Verstovsek. "Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study." Blood 134, Supplement_1 (2019): 2948. http://dx.doi.org/10.1182/blood-2019-124343.

Full text

Abstract:

Background The oral Janus kinase (JAK) 1/JAK2 inhibitor RUX has been shown to induce a reduction in bone marrow (BM) fibrosis in patients (pts) with myelofibrosis (MF) compared with placebo. MF is characterized by clonal proliferation of hematopoietic progenitor cells (HPCs) and amplification of cytokine-producing megakaryocytes (MEGs) and macrophages (MACs). Evidence suggests that the pro-inflammatory microenvironment, fostered by the hematopoietic clone, results in BM stromal alterations (including BM fibrosis and osteosclerosis), which can, in turn, influence the hematopoietic niche. The ob

APA, Harvard, Vancouver, ISO, and other styles

35

Garcia-Manero, Guillermo, Koji Sasaki, Guillermo Montalban-Bravo, et al. "A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)." Blood 132, Supplement 1 (2018): 465. http://dx.doi.org/10.1182/blood-2018-99-119424.

Full text

Abstract:

Abstract Introduction: Myeloid cells express PD1 and CTL-A. The expression of these molecules is activated by treatment with a hypomethylating agent (HMA) both in cell lines and patient samples. We hypothesized that treatment of patients with MDS with immune checkpoint inhibitors (ICPI) blocking CTLA or PD1 with or without azacitidine could have activity both in front line and relapsed MDS. Methods: To study this, we designed a basket exploratory phase 2 trial of ICPI in MDS. Patients with MDS age 18 or older with adequate renal and hepatic function without history of autoimmune disorders were

APA, Harvard, Vancouver, ISO, and other styles

36

Hui, Gavin, Abdullah Ladha, Edna Cheung, et al. "Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML." Blood 136, Supplement 1 (2020): 36–37. http://dx.doi.org/10.1182/blood-2020-142691.

Full text

Abstract:

Introduction: The addition of gemtuzumab ozogamicin (GO) to 7+3 chemotherapy for newly diagnosed acute myeloid leukemia (AML) has been shown to significantly improve event-free survival (EFS) for cytogenetically favorable-risk AML, with marginal benefit for intermediate-risk AML, and no benefit for cytogenetically adverse-risk AML. Of note, with the exception of mutated FLT3-ITD, little is known about the impact of GO in ELN 2017-defined genotypically adverse-risk AML, and a recent randomized trial found no EFS benefit for 7+3+GO in patients (pts) with genotypically favorable-risk, NPM1-mutate

APA, Harvard, Vancouver, ISO, and other styles

37

Condit, Celeste M. "How the public understands genetics: non-deterministic and non-discriminatory interpretations of the “blueprint” metaphor." Public Understanding of Science 8, no. 3 (1999): 169–80. http://dx.doi.org/10.1088/0963-6625/8/3/302.

Full text

Abstract:

Critics have worried that recent mass media coverage of genetics encourages genetic determinism and discriminatory attitudes in the public. They have identified the “blueprint” metaphor as one major component of public discourse that encourages such undesirable public opinions. To assess public interpretations of popular discourse about genetics, this audience study exposed 137 college students to sample genetics news articles and asked for their interpretations of the “blueprint” metaphor and of genetics in general. A larger group, the plurality, offered non-deterministic interpretations and

APA, Harvard, Vancouver, ISO, and other styles

38

O'Sullivan, Jennifer, Jason A. Taylor, Aaron T. Gerds, et al. "Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib." Blood 134, Supplement_1 (2019): 4214. http://dx.doi.org/10.1182/blood-2019-129254.

Full text

Abstract:

PAC203 is a global multicenter dose-finding study of pacritinib (PAC), an oral JAK2/IRAK1 inhibitor in patients with primary or secondary myelofibrosis refractory or intolerant to ruxolitinib, including patients with severe thrombocytopenia. Patients were randomized 1:1:1 (PAC 100mg QD, 100mg BID or 200mg BID) and stratified by baseline platelet count. The mutational landscape of this patient group is not well characterised, and the impact of mutation status on disease response and hematologic parameters is unknown. We carried out baseline mutational analysis on 105 (of total 164 recruited; 16

APA, Harvard, Vancouver, ISO, and other styles

39

Abrams, John M. "An emerging blueprint for apoptosis in Drosophila." Trends in Cell Biology 9, no. 11 (1999): 435–40. http://dx.doi.org/10.1016/s0962-8924(99)01646-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Wood, Christopher. "Pearce, David (ed.), "Blueprint 3: Measuring Sustainable Development" (Book Review)." Town Planning Review 66, no. 2 (1995): 213. http://dx.doi.org/10.3828/tpr.66.2.j1024176427770v5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Adam, Marc T. P., Henner Gimpel, Alexander Maedche, and René Riedl. "Design Blueprint for Stress-Sensitive Adaptive Enterprise Systems." Business & Information Systems Engineering 59, no. 4 (2016): 277–91. http://dx.doi.org/10.1007/s12599-016-0451-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Zuvanov, Luíza, Diogo Maciel Duarte Mota, Ana P. U. Araujo, and Ricardo DeMarco. "A blueprint of septin expression in human tissues." Functional & Integrative Genomics 19, no. 5 (2019): 787–97. http://dx.doi.org/10.1007/s10142-019-00690-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Hook, Brian. "The Hong Kong Basic Law: Blueprint for “Stability and Prosperity” under Chinese Sovereignty? Edited by Ming K. Chan and David J. Clark. [Armonk, NY: M. E. Sharpe, 1991. 310 pp. $45.00. ISBN 0 87332 835 3.] - Education and Society in Hong Kong: Toward One Country and Two Systems. Edited by Gerard A. Postiglione with Julian Leung Yat Ming [Armonk, NY: M. E. Sharpe, 1991. 320 pp. $45.00. ISBN 0 87332 743 8.]." China Quarterly 134 (June 1993): 371–73. http://dx.doi.org/10.1017/s0305741000029842.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

WACKERS, F., and T. BATEMAN. "Blueprint of the certification examination in nuclear cardiology." Journal of Nuclear Cardiology 4, no. 2 (1997): 164–68. http://dx.doi.org/10.1016/s1071-3581(97)90066-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Whitworth, Pat W., Mark Gittleman, Stephanie Akbari, et al. "Chemosensitivity and endocrine sensitivity prediction by MammaPrint and BluePrint in the Neoadjuvant Breast Registry Symphony Trial (NBRST)." Journal of Clinical Oncology 32, no. 26_suppl (2014): 29. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.29.

Full text

Abstract:

29 Background: Classification into molecular subtypes is important for the selection of therapy for patients with breast cancer. Previous analyses demonstrated that breast cancer subtypes have distinct clinical outcome (Gluck, BCRT 2013). The aim of the prospective NBRST study is to measure chemosensitivity as defined by pathologic complete response (pCR), or endocrine sensitivity as defined by partial response (PR) and metastasis-free survival in molecular subgroups. Methods: The study includes women aged 18 to 90 with histologically proven breast cancer, who are scheduled to start neoadjuvan

APA, Harvard, Vancouver, ISO, and other styles

46

Jacobson, Caron A., Alex F. Herrera, Lihua E. Budde, et al. "Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy." Blood 134, Supplement_1 (2019): 4107. http://dx.doi.org/10.1182/blood-2019-128203.

Full text

Abstract:

Background: Adoptive engineered autologous cellular immunotherapy has had a significant impact on the lives of some patients with advanced hematologic malignancies. However, the use of these therapies on a larger proportion of patients has been limited by variability of the final cell product, feasibility concerns, cost, and toxicity. Off-the-shelf allogeneic (allo) products offer the opportunity to address some of these concerns. Allo products have their own theoretical limitations, including the potential for graft-versus-host disease (GvHD) causing additional toxicity and host-versus-graft

APA, Harvard, Vancouver, ISO, and other styles

47

Rausch, Caitlin R., Adam DiPippo, Prithviraj Bose, and Dimitrios P. Kontoyiannis. "Breakthrough Invasive Fungal Infections (bIFI) Are Uncommon in Patients with Newly Diagnosed Acute Leukemia Receiving Primary Antifungal Prophylaxis." Blood 136, Supplement 1 (2020): 31–32. http://dx.doi.org/10.1182/blood-2020-142559.

Full text

Abstract:

Introduction: Mold-active primary antifungal prophylaxis (PAP) is widely recommended in neutropenic patients (pts) with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) who undergo remission-induction chemotherapy (RIC). Posaconazole (PCZ) prophylaxis resulted in fewer invasive fungal infections (IFIs) when compared to fluconazole and was associated with a survival advantage in this population (Cornely et al, 2007). Similarly, pts with acute lymphoblastic leukemia (ALL) undergoing RIC are also at risk of IFI due to prolonged neutropenia. Although PCZ is

APA, Harvard, Vancouver, ISO, and other styles

48

Wang, Xiaoli, Raajit K. Rampal, Cing Siang Hu, et al. "The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells." Blood 134, Supplement_1 (2019): 1677. http://dx.doi.org/10.1182/blood-2019-128836.

Full text

Abstract:

MPN-BP originates from a leukemic stem cell (LSC) that is capable of recreating and serial passaging the leukemia in NSG mice (Wang Blood 2018). The genomic architecture of these LSCs has not been well characterized. We therefore performed mutational profiling using capture-based next generation sequencing of primary MPN-BP patient samples and xenografts following their transplantation into NSG mice. All 7 patients with MPN-BP studied had 2-6 known oncogenic gene mutations. T cell-depleted mononuclear cells (MNC, 1-10×106) containing 50-3850 leukemia initiating cells based upon limiting diluti

APA, Harvard, Vancouver, ISO, and other styles

49

Verstovsek, Srdan, Anne Jacobson, Jeffrey D. Carter, and Tamar Sapir. "Facilitating Team-Based Care Coordination and Collaboration in Myelofibrosis: Findings from a Quality Improvement Study in Three US Community Oncology Systems." Blood 136, Supplement 1 (2020): 32–33. http://dx.doi.org/10.1182/blood-2020-136432.

Full text

Abstract:

Background Care coordination can be especially challenging in the setting of rare malignancies such as myelofibrosis (MF), where hematology/oncology teams have limited experience working together to implement rapidly evolving standards of care. In this quality improvement (QI) initiative, we assessed barriers to patient-centered MF care in 3 community oncology systems and conducted team-based audit-feedback (AF) sessions within each system to facilitate improved care coordination. Methods Between 1/2020 and 3/2020, 31 hematology/oncology healthcare professionals (HCPs) completed surveys design

APA, Harvard, Vancouver, ISO, and other styles

50

Zhao, Mansuo, Yibing Yang, and Hong Yan. "An adaptive thresholding method for binarization of blueprint images." Pattern Recognition Letters 21, no. 10 (2000): 927–43. http://dx.doi.org/10.1016/s0167-8655(00)00052-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!